Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.US-based CardioVascular BioTherapeutics has dosed the first patient in North America as part of its Acord Phase II clinical trial to treat patients with severe coronary heart disease.
Subscribe to our email newsletter
The Acord trial will include four randomized, double-blind, placebo-controlled doses in approximately 120 patients with severe coronary heart disease. Approximately 30 sites are expected to participate.
CardioVascular BioTherapeutics’s (CVBT) drug candidate (CVBT-141H) contains a human protein, Fibroblast Growth Factor-1 (FGF-1), that will be injected into patients’ hearts with the intent to stimulate a healing process called angiogenesis. The drug will be targeted and delivered using the 3-D mapping Noga XP cardiac navigation system and the MyoStar injection catheter.
Daniel Montano, CEO of CVBT, said: “Although it has taken longer than expected to reach this milestone, I am delighted that our Phase II heart trial is finally underway. Dosing the first patients is a major advancement in the development and verification of our drug.”